Insights

Innovative Technology NEC OncoImmunity AS specializes in AI-driven software for personalized cancer immunotherapy, presenting a unique value proposition for biotech and pharmaceutical companies seeking advanced precision medicine solutions.

Strategic Collaborations Recent partnerships with Nagasaki University and collaborations on SARS-CoV-2 vaccine development indicate strong access points to academic and healthcare sectors, offering potential for joint ventures and research grants.

Recent Asset Acquisition The company's acquisition of neoantigen vaccine development assets from VAXIMM highlights their expansion into vaccine technology, creating opportunities to position complementary products or services in the immunotherapy market.

Funding and Growth With nearly $4.8 million in recent funding from global health initiatives and private investors, NEC OncoImmunity demonstrates financial stability and growth potential, appealing to partners interested in early-stage biotech innovations.

Market Positioning Operating in the competitive biotech space with a focus on personalized cancer treatments, NEC OncoImmunity’s technological edge and collaborative projects position it as a promising partner for organizations aiming to expand into immunotherapy and vaccine development markets.

NEC OncoImmunity AS Tech Stack

NEC OncoImmunity AS uses 8 technology products and services including GitHub, Docker, Open Graph, and more. Explore NEC OncoImmunity AS's tech stack below.

GitHub

Communication And Collaboration

Docker

Containerization

Open Graph

Content Management System

JSON-LD

Javascript Frameworks

Python

Programming Languages

HSTS

Security

pytest

Testing And Qa

Google Plus

Widgets

NEC OncoImmunity AS Email Formats	Example	Percentage
First@oncoimmunity.com	John@oncoimmunity.com	100%

NEC OncoImmunity AS Email Formats

Example

Percentage

First@oncoimmunity.com

John@oncoimmunity.com

100%

Frequently Asked Questions

Where is NEC OncoImmunity AS's headquarters located?

NEC OncoImmunity AS's main headquarters is located at Ullernchausséen 64, Oslo, Oslo 0379, NO. The company has employees across 2 continents, including EuropeAsia.

What is NEC OncoImmunity AS's official website and social media links?

NEC OncoImmunity AS's official website is nec-bio.com and has social profiles on LinkedIn Crunchbase.

What is NEC OncoImmunity AS's SIC code NAICS code?

NEC OncoImmunity AS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NEC OncoImmunity AS have currently?

As of October 2025, NEC OncoImmunity AS has approximately 44 employees across 2 continents, including EuropeAsia. Key team members include Chief Executive Officer: S. N.Chief Scientific Officer: K. B.Co-Founder And Advisor: R. S.. Explore NEC OncoImmunity AS's employee directory with LeadIQ.

What industry does NEC OncoImmunity AS belong to?

NEC OncoImmunity AS operates in the Biotechnology Research industry.

What technology does NEC OncoImmunity AS use?

NEC OncoImmunity AS's tech stack includes GitHubDockerOpen GraphJSON-LDPythonHSTSpytestGoogle Plus.

What is NEC OncoImmunity AS's email format?

NEC OncoImmunity AS's email format typically follows the pattern of First@oncoimmunity.com. Find more NEC OncoImmunity AS email formats with LeadIQ.

How much funding has NEC OncoImmunity AS raised to date?

As of October 2025, NEC OncoImmunity AS has raised $4.8M in funding. The last funding round occurred on Apr 08, 2022 for $4.8M.

When was NEC OncoImmunity AS founded?

NEC OncoImmunity AS was founded in 2014.

NEC OncoImmunity AS

Biotechnology ResearchNorway11-50 Employees

NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines.
We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time frame.
Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers.
NEC OncoImmunity AS is a subsidiary of the NEC Corporation, and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.

Insights

Similar companies to NEC OncoImmunity AS

Cue Biopharma